Russell 1000 Financial Services (Rgs) Index (RIFIN) Cours

Form 8-K - Current report

AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif., Aug. 6, 2024 THOUSAND OAKS, Calif., Aug. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced...

AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND

AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND PR Newswire THOUSAND OAKS, Calif., Aug. 2, 2024 THOUSAND OAKS, Calif., Aug. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board...

AMGEN ANNOUNCES WEBCAST OF 2024 SECOND QUARTER FINANCIAL RESULTS

AMGEN ANNOUNCES WEBCAST OF 2024 SECOND QUARTER FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif., Aug. 1, 2024 THOUSAND OAKS, Calif., Aug. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...

Form 4 - Statement of changes in beneficial ownership of securities

FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE

FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE PR Newswire THOUSAND OAKS...

Form S-8 - Securities to be offered to employees in employee benefit plans

AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024

AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024 PR Newswire THOUSAND OAKS, Calif., June 12, 2024 Data Highlight Positive Outcomes in Uncontrolled Gout With KRYSTEXXA® and Progress...

AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., June 5, 2024 THOUSAND OAKS, Calif., June 5, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN...

AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)

AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD) PR Newswire THOUSAND OAKS...